Clinical trial NCT06217822: First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Official title: A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of 225Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Metastatic Castration-resistant Prostate Cancer
Prostate Specific Membrane Antigen (PSMA) Expression
Keywords: mCRPC
PSMA
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2024-01-23
Enrollment: 235
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC).

mCRPC is a cancer of the prostate (male reproductive gland found below the bladder) that has spread to other parts of the body. This type of prostate cancer does not respond to hormone treatment used to lower the level of testosterone, a male sex hormone, to prevent cancer from growing.

The study treatment 225Ac-PSMA-Trillium, also called BAY3563254, is under development to treat advanced metastatic castration-resistant prostate cancer. It works by binding to PSMA and giving off radiation that can damage cancer cells and stop them from growing.

The main purpose of this first-in-human study is to learn:

* How safe is BAY3563254 in participants.
* What is the recommended dose of BAY3563254 that is safe and works well that will be further tested in Part 2 of the study.
* How well does BAY3563254 work in participants.

To answer this, the researchers will look at:

* The number and severity of medical problems including serious medical problems that participants experience after taking BAY3563254
* The number of dose-limiting toxicities (DLT) at each dose level. A DLT is a medical problem caused by a drug that is too severe to continue the use of that specific dose.
* The number of participants whose cancer completely disappears (complete response) or reduces by at least 30% (partial response) after taking the treatment (also known as objective response rate (ORR))
* The number of participants who have a decrease in the levels of PSA\* by at least 50% in their blood (also known as PSA50). PSA is a protein made by the prostate gland. High levels of PSA may indicate the presence of prostate cancer.
* Participants' best response to treatment based on their PSA levels (also known as the best overall PSA response).

The study will have two parts. The first part, called dose escalation, is done to find the most appropriate dose of BAY3563254 for use in the second part of the study. For this, each participant will receive one of different increasing amounts of BAY3563254. They will take BAY3563254 as an injection into a vein. All participants in the second part of the study, called dose expansion, will receive the most appropriate dose of BAY3563254 that was identified from the first part of the study.

Participants in this study will take the study treatment once every 6 weeks, which is known as a treatment cycle. Each participant will have up to 4 of these treatment cycles, if the participant benefits from the treatment. Each participant will be in the study for approximately 6 years, including a screening phase of up to 30 days, 6 months of treatment depending on the participant's benefit, and a follow up phase of 60 months after the end of treatment.

In addition, substudies performed during both dose escalation and dose expansion parts of the study will evaluate:

* the clearance of radioactivity from the body over time
* the doses of radiation that are delivered to normal organs and tumors

During the study, the doctors and their study team will:

* take blood and urine samples
* check vital signs such as blood pressure, heart rate, and body temperature
* examine heart health using electrocardiogram (ECG)
* take tumor samples if required
* check if the participants' cancer has grown and/or spread using CT (computed tomography) or MRI (magnetic resonance imaging) and bone scan
* check the tumor status using PET (positron emission tomography)
* check the amount of radiation absorbed by tumors and normal organs using SPECT/CT (single-photon emission tomography and computed tomography scan)
* ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.

The treatment period ends with a visit in 6-12 weeks after the last BAY3563254 dose. About 6-12 weeks after the last dose and every 6 weeks thereafter, the study doctors and their team will check the participants' health and any changes in their cancer. This active follow-up period ends after 18 months. The long-term follow-up period will start after the end of the active follow-up visit and will continue for up to 60 months after the the last BAY3563254 dose. Participants will be contacted, typically by phone call or clinic visit, approximately every 12 weeks after the end of active follow-up.


Eligibility criteria: Inclusion Criteria:

* mCRPC with pathological confirmation of adenocarcinoma without small-cell or neuroendocrine features.
* Documented progressive mCRPC per PCWG3, defined when at least one of the following criteria is met:

  * PSA progression (defined as 2 consecutive increases over a previous reference value obtained at a minimum of 1-week intervals, with a minimum starting value of 1.0 ng/mL)
  * Radiological progression in soft-tissue lesions according to PCWG3 modification of RECIST v1.1 criteria
  * Progression of bone disease (defined as ≥ 2 new bone lesions according to PCWG3 bone scan criteria)
* Previous treatment with at least 1 novel androgen axis drug (NAAD) (e.g., enzalutamide, apalutamide, darolutamide and/or abiraterone).
* Prior orchiectomy and/or ongoing androgen deprivation therapy and a castrate level of serum testosterone (\<50 ng/dL or \<1.7 nmol/L).
* Prior taxane treatment:

  * Dose Escalation: Participants must either have had prior treatment with at least 1 but no more than 2 taxane regimens, or been deemed ineligible for or refused taxane therapy on consultation with their physician
  * Dose Expansion Group A: Participants must have had prior treatment with at least 1 but no more than 2 taxane regimens, in the castration-resistant setting
* Dose Expansion Group B: Participants must not have received any taxane regimens since becoming castration-resistant

  * Dose Expansion Group C: Participants must either have had prior treatment with at least 1 but no more than 2 taxane regimens, or been deemed ineligible for or refused taxane therapy on consultation with their physician
* Prior treatment with an established Lu-PSMA therapy (i.e., dose activity and cycles comparable to approved treatments) is required for participants in Dose Expansion Group C only. More specifically, to qualify for this expansion group, participants must meet all of the following criteria:

  * Received a minimum of two cycles of Lu-PSMA
  * Not discontinued Lu-PSMA treatment due to intolerance; and • Not achieved a PSA50 or partial /complete response on radiographic assessment during the course of 7Lu-PSMA treatment..
* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
* Adequate bone marrow, hepatic, and renal function, as assessed by the following laboratory requirements within 30 days before start of study intervention, as indicated below. Note that blood transfusions (red blood cells or platelets) and administration of G-CSF or GM-CSF are prohibited within 21 days prior to screening for the below bone marrow-related parameters.

  * Hemoglobin ≥9.0 g/dL
  * Absolute neutrophil count (ANC) ≥1500/mm\^3
  * Platelet count ≥100,000/mm\^3
  * Total bilirubin ≤1.5 x the Upper limit of normal (ULN), or ≤3×ULN if the participant has a confirmed history of Gilbert's syndrome (note that participants with Gilbert's syndrome should be carefully evaluated for other liver-related disorders that may impact their suitability for this study).
  * Alanine transaminase (ALT) and Aspartate transaminase (AST) ˂2.5 x ULN (≤5 x ULN for participants with liver involvement)
  * Participants on a stable dose of anticoagulation therapy are allowed to participate if they have no sign of bleeding or clotting, and prothrombin time international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT) test results are acceptable at the Investigator's discretion
  * Estimated glomerular filtration rate (eGFR) \>60 mL/min/1.73 m\^2, according to the Modified Diet in Renal Disease (MDRD) abbreviated formula and serum creatinine ≤1.5 x ULN
* Participants must have at least one PSMA-positive (prostate-specific membrane antigen) distant metastatic lesion on the screening PSMA PET/CT scan using the study-designated PSMA PET tracers, as determined by the site Investigator. For eligibility purposes, a PSMA-positive lesion must have activity greater than the liver by visual assessment of the screening PSMA PET/CT. A PSMA-positive metastatic lesion should not correspond to a normal tissue structure or benign lesion.

Exclusion Criteria:

* Participants who have any of the following tumor lesions which are PSMA negative AND meet the size criteria below are excluded as determined by the site Investigator. A PSMA-negative lesion for eligibility purposes must have activity equal to or less than the liver by visual assessment of the screening PSMA PET/CT scan using the study-designated PSMA PET/CT tracers. A PSMA-negative metastatic lesion should not correspond to a normal tissue structure or benign lesion.

  * a. Any single or multiple lymph node(s) ≥2.5 cm in the short axis.
  * b. Any solid organ metastasis (e.g., lung, liver, adrenal glands, etc.) that is ≥1 cm in the short axis.
  * c. Any bone metastasis with a soft tissue component ≥ 1 cm in short axis with the soft tissue component being PSMA-negative. PSMA-negative osseous metastases without a soft tissue component do not exclude a participant.
  * d. Predominantly necrotic lesions with greater than 1 cm of enhancing tissue on contrast-enhanced computed tomography / magnetic resonance imaging (CT/MRI).
* Prior systemic anticancer therapy including chemotherapy, NAAD, biologic therapy, immunotherapy, or investigational therapies within 4 weeks of the start of study treatment, except luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH). Start of study treatment is allowed in shorter timeframes if 5 half-lives of the prior drug(s) have elapsed.
* Prior radiopharmaceutical treatment using actinium-225.

Other prior radiopharmaceutical treatments:

* Dose escalation and Dose expansion Groups A and B: Prior treatment with a radiopharmaceutical is prohibited, with the following exception: Prior treatment with radium-223 dichloride more than 3 months before the start of study intervention is permitted.
* Dose expansion Group C: Prior treatment with a radiopharmaceutical is prohibited with the following exceptions: Prior treatment with radium-223 dichloride more than 3 months before the start of study intervention is permitted; and prior treatment with Lu PSMA more than 6 weeks before the start of study intervention is required. Note: Participants who have discontinued Lu-PSMA treatment due to intolerance or loss of initial response are excluded from Group C.
* Prior definitive therapy (radiotherapy or surgery) completed less than 6 weeks before the start of study intervention. Note that palliative radiotherapy completed less than 6 weeks before the start of study intervention will be allowed if: (i) no more than 10% of the participants' bone marrow is irradiated, (ii) it does not encompass all potential target/measurable lesions for participants in dose expansion.
* Toxic effects of Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade ≥2 from prior anticancer therapy not yet stabilized or where significant post-treatment toxicities have been observed. Chronic toxic effects of CTCAE Grade ≤2 from prior anticancer therapy where no further resolution is expected do not require exclusion with agreement between the Investigator and Sponsor (e.g., chemotherapy-induced neuropathy, fatigue, alopecia, anorexia, etc.).

Primary outcomes:
measure: Dose Escalation and Dose Expansion: Incidence of TEAEs (including TESAEs)
timeFrame: After the first administration of study intervention up to 42 days after the last dose of study intervention
measure: Dose Escalation and Dose Expansion: Severity of TEAEs (including TESAEs)
timeFrame: After the first administration of study intervention up to 42 days after the last dose of study intervention
measure: Dose Escalation: Incidence of DLTs
timeFrame: Up to and including Cycle 3 (each cycle is 42 days)
measure: Dose Escalation and Dose Expansion: ORR by PCWG3 guideline based on Investigator review
timeFrame: Up to 18 months after end of treatment
measure: Dose Escalation and Dose Expansion: PSA50 response
timeFrame: At 12 weeks or later (up to 18 months after end of treatment)
measure: Dose Expansion: Best overall PSA response
timeFrame: Up to 18 months after end of treatment
Secondary outcomes:
measure: Dose Expansion: Recommended dose for further clinical development
timeFrame: Up to 18 months after end of treatment
measure: Dose Expansion: Recommended dose regimen for further clinical development
timeFrame: Up to 18 months after end of treatment
measure: Dose Escalation and Dose Expansion: Radiologic progression-free survival (rPFS) by PCWG3 based on Investigator review
timeFrame: Up to 18 months after end of treatment
measure: Dose Escalation and Dose Expansion: Duration of response (DOR) by PCWG3 based on Investigator review
timeFrame: Up to 18 months after end of treatment
measure: Dose Escalation and Dose Expansion: Duration of PSA50 response
timeFrame: Up to 18 months after end of treatment
measure: Dose Escalation and Dose Expansion: Cmax of 225Ac
timeFrame: Cycle 1, cycle 2 (From pre-dose up to Day 36 post-dose for each cycle)
measure: Dose Escalation and Dose Expansion: AUC and AUC(0-tlast) of 225Ac
timeFrame: Cycle 1, cycle 2 (From pre-dose up to Day 36 post-dose for each cycle)
measure: Dose Escalation and Dose Expansion: Cmax of PSMA-Trillium-macropa peptide
timeFrame: Cycle 1, cycle 2 (From pre-dose up to Day 36 post-dose for each cycle)
measure: Dose Escalation and Dose Expansion: AUC and AUC(0-tlast) of PSMA-Trillium-macropa peptide
timeFrame: Cycle 1, cycle 2 (From pre-dose up to Day 36 post-dose for each cycle)
Other outcomes:
Locations:
city: Anderlecht
country: Belgium
facility: Institut Jules Bordet / Nuclear Medicine
city: Kortrijk
country: Belgium
facility: AZ Groeninge Campus Kennedylaan - Urology
city: Edmonton
country: Canada
facility: Cross Cancer Institute, Clinical Trials Unit
state: Alberta
city: Vancouver
country: Canada
facility: BC Cancer - Vancouver Site
state: British Columbia
city: Hamilton
country: Canada
facility: Juravinski Cancer Centre - Clinical Trials Department
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology
state: Ontario
city: Montreal
country: Canada
facility: Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopi
state: Quebec
city: Montreal
country: Canada
facility: McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM)
state: Quebec
city: Sherbrooke
country: Canada
facility: Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hopital Fleurimont
city: Kuopio
country: Finland
facility: Kuopio University Hospital
state: Pohjois-Savo
city: Helsinki
country: Finland
facility: Helsinki University Hospital, Comprehensive Cancer Center
state: Uusimaa
city: Helsinki
country: Finland
facility: Docrates Mehiläinen Syöpäsairaala
state: Uusimaa
city: Tampere
country: Finland
facility: Tampere University Hospital
city: Turku
country: Finland
facility: Turku University Hospital
city: Milano
country: Italy
facility: Istituto Europeo di Oncologia s.r.l - Medicina Nucleare
city: Napoli
country: Italy
facility: IRCCS Istituto Nazionale Tumori Fondazione Pascale - S. C. Medicina Nucleare e Terapia Metabolica
city: Groningen
country: Netherlands
facility: Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center
city: Rotterdam
country: Netherlands
facility: Erasmus Medisch Centrum
city: Göteborg
country: Sweden
facility: Sahlgrenska Universitetssjukhuset - Klinisk prövningsenhet Fas I/FIH
city: Lund
country: Sweden
facility: Skånes Universitetssjukhus Lund - Onkologens kliniska forskningsenhet
city: Stockholm
country: Sweden
facility: Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC
city: Uppsala
country: Sweden
facility: Akademiska Sjukhuset - Fas-I-enheten
city: Baden
country: Switzerland
facility: Kantonsspital Baden
state: Aargau
city: Sutton
country: United Kingdom
facility: Royal Marsden NHS Trust (Surrey)
state: Surrey
city: London
country: United Kingdom
facility: University College London Hospitals NHS Foundation Trust
city: Newcastle
country: United Kingdom
facility: The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital
Study officials:
References: